

# SURPASS Trial Design:


## A Phase 1 Dose Escalation Trial to Assess Safety and Efficacy of ADP-A2M4CD8 in HLA-A2+ Patients with MAGE-A4+ Tumors

Paula M. Fracasso<sup>1</sup>, David Hong<sup>2</sup>, Marcus Butler<sup>3</sup>, Melissa Johnson<sup>4</sup>, Tanner Johanns<sup>5</sup>, Francine Brophy<sup>1</sup>, Rebecca Dryer-Minnerly<sup>1</sup>, Trupti Trivedi<sup>1</sup>

<sup>1</sup>Adaptimmune, Philadelphia, PA, USA, <sup>2</sup>MD Anderson Cancer Center, Houston, TX, USA, <sup>3</sup>Princess Margaret Cancer Centre, Toronto, ON, Canada, <sup>4</sup>Sarah Cannon, Nashville, TN, USA, <sup>5</sup>Washington University in St. Louis, St. Louis, MO, USA



An electronic copy of the poster can be viewed by scanning the QR code



### Background

- Next-generation SPEAR T-cells (ADP-A2M4CD8) target MAGE-A4+ tumors in the context of HLA-A\*02 (Figure 1)
- Engineered CD8α co-receptor increases the potency of CD4+ T-cell pre-clinical anti-tumor response (Central figure)

Figure 1. SPEAR T-cells





Figure 2. SURPASS study objectives

Primary	Evaluate the safety and tolerability of ADP-A2M4CD8 T-cell therapy
Secondary	Evaluate the anti-tumor activity of ADP-A2M4CD8 T-cells
Exploratory	Identify serum and tumor factors that influence response or resistance to ADP-A2M4CD8 therapy


### Improved targeting and killing of solid tumor cells

- Effectiveness demonstrated with first-generation engineered TCRs
- Now innovating to find ways of strengthening anti-tumor TCR responses

#### Next-generation SPEAR T-cell



#### First-generation SPEAR T-cell



Tumor cell targeting and killing

Enhanced engagement of the immune system

Treatment effect duration

SURPASS trial

Pre-clinical anti-tumor activity enhanced and response broadened

Next-generation strategies

Engineered TCRs

Immunotherapy for cancer


### SURPASS trial (NCT04044859)

- Recruiting up to 30 patients from North America and Europe
- Multiple solid tumor types; HLA-A\*02 and MAGE-A4 positive

### Trial Details


- This is a first-in-human, dose-escalation, open-label trial
- We are currently recruiting trial participants
- Study design and engineered T-cell pathway are shown below (Figure 3 and Figure 4)

Figure 3. SURPASS trial design



\*Patient is hospitalized for T-cell infusion for minimum of 3 days and discharged at the discretion of the Investigator

Figure 4. Patient cell journey



### Abbreviations

Abbreviations: DC, dendritic cell; HLA, human leukocyte antigen; MAGE-A4, melanoma-associated antigen-A4; PD, progressive disease; RECIST, response evaluation criteria in solid tumors; SPEAR, specific peptide enhanced affinity receptor; TCR, T-cell receptor

### Sponsor contact details:

- Paula M. Fracasso, MD, PhD
- (+1) 215-825-9260
- paula.fracasso@adaptimmune.com



SPEAR T-cell mechanism of action video can be viewed by scanning the QR code



Full trial details from ClinicalTrials.gov can be viewed by scanning the QR code